Abstract
Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer treatment and its incidence is growing. It significantly affects quality of life and is a dose-limiting factor that interferes with treatment. Its diagnosis can be established in clinical terms but some complementary tests can help when the diagnosis is difficult. There is still no proven method to prevent it that has become a standard of care in spite of the huge amount of investigation carried out in recent years. There are promising strategies that could help reduce the burden of this complication. This review will suggest an approach to the diagnosis of these disorders and provide an update on new therapies.
Similar content being viewed by others
References
Walker M, Ni O (2007) Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol 30:82–92
Cavaletti G, Bogliun G, Marzorati L et al (1994) Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 14:1287–1292
Mileshkin L, Antil Y, Rischin D (2002) Management of complications of chemotherapy. In: Gershenson DM, McGuire MP, Gore M et al (eds) Gynaecologic cancer: controversies in management. Elsevier Science, Philadelphia, PA
Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515
Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514
National Cancer Institute (NCI) (2006) Nerve changes in patients who are undergoing chemotherapy or biological therapy for cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show/NCT00281853?term=cancer+AND+neuropathy&rank=33
MD Anderson Cancer (2009) Chemotherapy-induced peripheral neuropathy survey. In: ClinicalTrials. gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show/NCT01016028?term=cancer+AND+neuropathy&rank=14
Gardner ED, Bunge RP (2005) Gross anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, Philadelphia, pp 11–34
Berthold SH, Fraher JP, King RHM et al (2005) Microscopic anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, Philadelphia, pp 35–91
Cecilia Conde C, Cáceres A (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10:319–332
Hughes R (2008) Peripheral nerve diseases. Pract Neurol 8:396–405
Serra Catafau J (2006) Concepto de dolor neuropático. In: Serra Catafau J (ed.) Dolor neuropático. Médica Panamericana, Madrid, pp 17–26
Devigili G, Tugnoli V, Penza P et al (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912–1925
Hughes R (2008) Peripheral nerve diseases. Pract Neurol 8:396–405
Pestronk A, Florence J, Levine T et al (2004) Sensory exam with a quantitative tuning fork. Rapid, sensitive and predictive of SNAP amplitude. Neurology 62:461–464
Martina IS, van Koningsveld R, Schmitz PI et al (1998) For the European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 65:743–747
Botez SA, Liu G, Logigian E et al (2009) Is the bedside timed vibration test reliable? Muscle Nerve 39:221–223
Zara G, Ermani M, Rondinone R et al (2008) Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 79:1258–1261
Postma TJ, Heimans JJ (2000) Grading of chemotherapy- induced peripheral neuropathy. Ann Oncol 11:509–513
Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advance colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478–3483
Park SB, Lin CS-Y, Krishnan AV et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132:2712–2723
Mileshkin L, Stark R, Day B et al (2006) Aparición de neuropatía en los pacientes con mieloma tratados con talidomida: patrones de aparición y utilidad de la monitorización electrofisiológica. J Clin Oncol 24:4507–4514
American Association of Electrodiagnostic Medicine (2004) Technology literature review: quantitative sensory testing. Muscle Nerve 29:734–747
Park SB, Goldstein D, Lin CS-Y et al (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27:1243–1249
Park SB, Krishnan AV, Lin CS-Y et al (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081–3094
England JD, Gronseth GS, Franklin G et al (2009) Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 39:106–115
Sommer C (2008) Skin biopsy as a diagnostic tool. Curr Opin Neurol 21:563–568
Lauria G, Devigili G (2007) Skin biopsy as a diagnostic tool in peripheral neuropathy. Nat Clin Pract Neurol 3:546–557
Lauria G, Lombardi R (2007) Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ 334:1159–1162
Erasmus Medical Center (2010) Skin biopsies in chemotherapy-induced neuropathy. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show?term=cancer+AND+neuropathy&rank=34
Ruzzo A, Graziano F, Loupakis F et al (2007) Perfil farmacogenético en los pacientes con cancer colorrectalavanzado tratados con quimioterapia FOLFOX-4 de primera línea. J Clin Oncol 25:1247–1254
Samsung Medical Center (2009) Pharmacogenomic study to predict neurotoxicity of oxaliplatin. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091220. Available from: http://clinicaltrials. gov/ct2/show/NCT00977717?term=neuropathy+and+chemotherapy&rank=32
Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642
Camps C, Felip E, Sanchez JM et al (2005) Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 16:597–601
Whitehead RP, McCoy S, Rivkin SE et al (2006) A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24:515–520
McKeage MJ, Hsu T, Screnci D et al (2001) Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85:1219–1225
Ta LE, Low PA, Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 26:5–9
Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842–2850
Cubillo S, Cabello A, Trueba JL et al (1980) Cisplatinum neuropathy. Neurosci Lett 4[Suppl]:447
McKeage K (2007) Treatment options for the management of diabetic painful neuropathy: best current evidence. Curr Opin Neurol 20:553–557
Hansen MB (2003) The enteric nervous system III: a target for pharmacological treatment. Pharmacol Toxicol 93:1–13
Krishnan AV, Kiernan MC (2006) Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve 33:627–636
McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228–244
Gutiérrez-Rivas E, Alonso-Ortiz A, Téllez I et al (1984) Vindesine-induced neuropathy. Neurosci Lett 18[Suppl]:40
Pan YA, Misgeld T, Lichtman JW et al (2003) Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci 23:11479–11488
Kalcioglu MT, Kuku I, Kaya E et al (2003) Bilateral hearing loss during vincristine therapy: a case report. J Chemother 15:290–292
Verstappen CC, Koeppen S, Heimans JJ et al (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076–1077
Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184–189
Cavaletti G, Nobile-Orazio E (2007) Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92:1308–1310
Moehler TM, Hillengass J, Glasmacher A et al (2006) Thalidomide in multiple myeloma. Curr Pharm Biotechnol 7:431–440
Rabasa M, Gutiérrez-Rivas E, Díaz J et al (1994) Neuropatía tóxica por Talidomida. Neurología 9:477
Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36
Openshaw H, Slatkin NE, Stein AS et al (1996) Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 78:1899–1905
Alonso-Ortiz A, Gutiérrez-Rivas E, Cabello A et al (1990) Toxic neuropathy induced by Ara-C. J Neurol Sci 98:265
Thant M, Hawley RJ, Smith MT et al (1982) Possible enhancement of vincristine neuropathy by VP-16. Cancer 1:859–864
Dormann AJ, Grunewald T, Wigginghaus B et al (1998) Gemcitabine-associated autonomic neuropathy. Lancet 351:644
Sherman JE, Aregawi MD, Lai A, Fathallah-Shaykh M (2009) Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73:1924–1926
Burnett AK, Kell J (2007) Tipifarnib in acute myeloid leukemia. Drugs Today (Barc) 43:795–800
Kovacs MJ, Reece DE, Marcellus D et al (2006) A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma: NCIC CTG IND.145. Invest New Drugs 24:529–535
Gutiérrez-Rivas E, Alonso-Ortiz A, Cabello A et al (1984) Toxic neuropathy due to prospidium. Neurosci Lett 18[Suppl]:403
Esteban PM, Thahn TG, Bravo JF et al (2009) Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr 52:656–658
Gomber S, Dewan P, Chhonker D (2009) Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr (published online)
de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947
de Gramont A, Cervantes A, Andre T et al (2004) OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. J Clin Oncol 22:3525
Ghirardi O, Lo Giudice P, Pisano C et al (2005) Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 25:2681–2687
Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746–1750
Daikhin Y, Yudkoff M (2000) Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr 130:1026S–1031S
Gedlicka C, Kornek GV, Schmid K et al (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 14:339–340
Leonetti C, Biroccio A, Gabellini C et al (2003) Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 104:243–250
Argyriou AA, Chroni E, Koutras A et al (2006) A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 14:1134–1140
Ferreira PR, Fleck JF, Diehl A et al (2004) Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 26:313–321
MD Anderson Cancer Center (2005) Alpha-lipoic acid in preventing peripheral neuropathy in patients receiving chemotherapy for cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show/NCT00112996?term=neuropathy+and+chemotherapy&rank=22
So YT, Simon RP (2007) Deficiency diseases of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM et al (eds) Neurology in clinical practice, 5th edn. Butterworth-Heinemann, Philadelphia, pp 1643–1656
Ang CD, Alviar MJM, Dans AL et al (2008) Vitamina B para el tratamiento de la neuropatía periférica (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, Número 4. Update Software Ltd., Oxford. Available from: http://www.update-software.com (Traducida de The Cochrane Library, 2008 Issue 3. John Wiley & Sons, Ltd., Chichester, UK)
New Mexico Cancer Care Alliance (2008) A randomized phase III study of vitamins B6 and B12 to prevent chemotherapy-induced neuropathy in cancer patients. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091222. Available from: http://clinicaltrials.gov/ct2/show/NCT00659269?term=neuropathy+and+chemotherapy&rank=3
Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. J Periph Nerv Syst 14:184–189
Kore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207–4213
Argyriou AA, Chroni E, Polychronopoulos P et al (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67:2253–2255
Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061
Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1:249–258
Hamers FP, Brakkee JH, Cavalletti E et al (1993) Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53:544–549
Cassidy J, Bjarnason G, Hickish T et al (2006) Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5FU/LV combination in first line treatment of patients with metastatic colorectal cancer. J Clin Oncol 24:3507. Abstr 229
Traa BS, Mulholland JD, Kadam SD et al (2008) Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. Pediatr Res 64:81–85
Cassidy J, Paul J, Soukop M et al (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharamacol 41:161–166
Hilton DJ (1992) LIF: lots of interesting functions. Trends Biochem Sci 17:72–76
Mamiya N, Kono T, Mamiya K et al (2007) A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer. Gan To Kagaku Ryoho 34:1295–1297
Shindo Y, Tenma K, Imano H et al (2008) Reduction of oxaliplatin-related neurotoxicity. Gan To Kagaku Ryoho 35:863–865
van der Hoop RG, Vetch GJ, van der Burg ME et al (1990) Prevention of cisplatin neurotoxicity with ovarian cancer. N Engl J Med 322:89–94
Jackson JH (1932) Evolution and dissolution of the nervous system (Croonian Lecture). Selected writings of John Hughlings Jackson, vol. 2. Hodder and Stoughton, London
Author information
Authors and Affiliations
Corresponding author
Additional information
Both authors have participated equally to this study
Rights and permissions
About this article
Cite this article
Gutiérrez-Gutiérrez, G., Sereno, M., Miralles, A. et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12, 81–91 (2010). https://doi.org/10.1007/S12094-010-0474-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/S12094-010-0474-z